The use of CLRs ligands (usually carbohydrates) to modify the delivery system will result in more direct targeting of antigens to specific DCs, thus enhancing antigen uptake.95 For example, mannose-modified polymers for delivery of melanoma antigenic peptides strongly induce prophylactic and therapeutic antitumor immune responses in melanoma models.96 Another example, CDX-1401 is a vaccine consisting of a DEC-205-specific monoclonal antibody fused to the full-length tumor antigen NY-ESO-1. Here, LARS1 is linked to melanoma.